Curesponse

The first Genomic-Functional Drug Sensitivity Platform for Cancer Patients

[Curesponse @CuresponseLtd]

How can you help your oncologist to prioritize treatment options?
Huge thanks to the Jerusalem Post for raising the importance of taylored personalised medicin and sharing our technology

https://t.co/WYFqcX5POR

[Curesponse @CuresponseLtd]

Check out our test!! Exited to share the new and advance persolisedlised medicin

https://t.co/Fofnme44cP

[The Jerusalem Post @Jerusalem_Post]

An Israeli technology developed at the @WeizmannScience makes it possible to determine which drug treatment will be most beneficial for an individual cancer patient and which will not.
For more information >>
https://t.co/ZNgYv8j6LO

[Curesponse @CuresponseLtd]

Thanks @YedaWeizmann!
https://t.co/vykgwJbAQl

[Straussman_Lab @StraussmanR]

Good luck CuResponse London!

[The ICR @ICR_London]

We’re very pleased to welcome a new medtech company @CuresponseLtd to the Innovation Gateway at The London Cancer Hub, a project led by us and the @SuttonCouncil in south London.

Their research could help cancer patients get the #PersonalisedTreatment they need.

[Curesponse @CuresponseLtd]

@StraussmanR @NatureComms Amazing work !!!

[Straussman_Lab @StraussmanR]

(1/3) Our new paper @NatureComms introduces the ‘Signalome’ cell lines. These cell lines use ‘visual barcodes’ for live tracking of the activity of a dozen signaling pathways in single-cell resolution, all from a single well in a multi-well plate. https://t.co/AhIiPqzfw1.

[Straussman_Lab @StraussmanR]

(4/7) Thanks to Marius Nacht’s generosity we opened @CuresponseLtd which runs clinical trials and recently made the technology available to cancer patients in Israel and abroad. It is highly rewarding when patients share with us the benefit they gained by the test. Less guessing!

[Curesponse @CuresponseLtd]

@StraussmanR Congratulations @StraussmanR. Very pround of your work and looking forward to continue helping cancer patients.

[Curesponse @CuresponseLtd]

https://t.co/SFbqoV2Zpt